CN120168449A - 苏糖酸镁组合物及其用途 - Google Patents

苏糖酸镁组合物及其用途 Download PDF

Info

Publication number
CN120168449A
CN120168449A CN202510100404.6A CN202510100404A CN120168449A CN 120168449 A CN120168449 A CN 120168449A CN 202510100404 A CN202510100404 A CN 202510100404A CN 120168449 A CN120168449 A CN 120168449A
Authority
CN
China
Prior art keywords
dosage form
magnesium
threonate
day
lbm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510100404.6A
Other languages
English (en)
Chinese (zh)
Inventor
刘国松
毛飞
J·G·温格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocentria Inc
Original Assignee
Neurocentria Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocentria Inc filed Critical Neurocentria Inc
Publication of CN120168449A publication Critical patent/CN120168449A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202510100404.6A 2018-04-25 2019-04-24 苏糖酸镁组合物及其用途 Pending CN120168449A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862662756P 2018-04-25 2018-04-25
US62/662,756 2018-04-25
PCT/US2019/028903 WO2019209943A1 (en) 2018-04-25 2019-04-24 Magnesium threonate compositions and uses thereof
CN201980042120.9A CN112384210A (zh) 2018-04-25 2019-04-24 苏糖酸镁组合物及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980042120.9A Division CN112384210A (zh) 2018-04-25 2019-04-24 苏糖酸镁组合物及其用途

Publications (1)

Publication Number Publication Date
CN120168449A true CN120168449A (zh) 2025-06-20

Family

ID=68291941

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202510100404.6A Pending CN120168449A (zh) 2018-04-25 2019-04-24 苏糖酸镁组合物及其用途
CN202510100476.0A Pending CN120241690A (zh) 2018-04-25 2019-04-24 苏糖酸镁组合物及其用途
CN201980042120.9A Pending CN112384210A (zh) 2018-04-25 2019-04-24 苏糖酸镁组合物及其用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202510100476.0A Pending CN120241690A (zh) 2018-04-25 2019-04-24 苏糖酸镁组合物及其用途
CN201980042120.9A Pending CN112384210A (zh) 2018-04-25 2019-04-24 苏糖酸镁组合物及其用途

Country Status (9)

Country Link
US (2) US11717501B2 (cg-RX-API-DMAC10.html)
EP (1) EP3784227A4 (cg-RX-API-DMAC10.html)
JP (2) JP2021522344A (cg-RX-API-DMAC10.html)
KR (1) KR20210005662A (cg-RX-API-DMAC10.html)
CN (3) CN120168449A (cg-RX-API-DMAC10.html)
AU (2) AU2019261406A1 (cg-RX-API-DMAC10.html)
BR (1) BR112020021812A2 (cg-RX-API-DMAC10.html)
CA (1) CA3098360A1 (cg-RX-API-DMAC10.html)
WO (1) WO2019209943A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3784227A4 (en) 2018-04-25 2022-03-02 Neurocentria, Inc. MAGNESIUM THREONATE COMPOSITIONS AND THEIR USES
WO2021245697A1 (en) 2020-06-01 2021-12-09 Celagenex Research (India) Pvt. Ltd. Novel synergistic medicinal compositions for treating dysfunctional d-serine signaling
KR20230058095A (ko) * 2020-08-28 2023-05-02 디에프아이 유에스에이, 엘엘씨. L-크실론산으로부터 l-트레온산 염을 생산하는 방법
CN115047058A (zh) * 2021-03-09 2022-09-13 江苏开元药业有限公司 一种测定铝碳酸镁咀嚼片溶出曲线的方法
CN114304610A (zh) * 2021-12-24 2022-04-12 苏州麦轮生物科技有限公司 一种含有苏糖酸镁的营养补充剂及其应用
WO2024232931A1 (en) * 2023-05-11 2024-11-14 Yon Doo Ough Apparatus and method for contact free delivery and administration of magnesium as a drug
CN119504413A (zh) * 2025-01-20 2025-02-25 浙江天启生化股份有限公司 一种l-苏糖酸镁合成方法及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
GB0009522D0 (en) * 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
DK1524981T3 (da) * 2002-07-29 2009-06-22 Glaxo Group Ltd Sammensætninger med vedvarende frigivelse indeholdende lamotrigin
AU2008227465B2 (en) * 2007-03-22 2014-02-06 Magceutics, Inc. Magnesium compositions and uses thereof
US8142803B2 (en) * 2007-03-22 2012-03-27 Magceutics, Inc. Magnesium compositions and uses thereof for neurological disorders
WO2011003045A1 (en) * 2009-07-01 2011-01-06 Magceutics, Inc. Slow release magnesium composition and uses thereof
US9943489B2 (en) * 2010-02-03 2018-04-17 Pharmatwob Ltd. Extended release formulations of rasagiline and uses thereof
CN108289875A (zh) 2015-09-11 2018-07-17 纽罗森特里亚股份有限公司 苏糖酸盐化合物及其使用方法
CN105326855A (zh) 2015-10-27 2016-02-17 南京大学 易吸收复合夹层式螯合镁钙片
CN105326955B (zh) * 2015-11-02 2019-04-12 北京市眼科研究所 一种治疗睑缘炎的组合物及其制备方法
US10617713B2 (en) 2016-03-08 2020-04-14 Neurocentria, Inc. Methods of modifying neuronal function by changing intracellular magnesium levels
CN107625776A (zh) 2016-07-19 2018-01-26 无锡脑镁素生物医药科技有限公司 用于改善睡眠的镁组合物及其用途
CN106360734A (zh) 2016-09-28 2017-02-01 张家港威胜生物医药有限公司 一种同时具有减肥和美容作用的组合物及其制备方法与用途
WO2018200885A1 (en) 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use
EP3784227A4 (en) 2018-04-25 2022-03-02 Neurocentria, Inc. MAGNESIUM THREONATE COMPOSITIONS AND THEIR USES

Also Published As

Publication number Publication date
AU2019261406A1 (en) 2020-12-17
US11717501B2 (en) 2023-08-08
US20240156761A1 (en) 2024-05-16
US20190328689A1 (en) 2019-10-31
EP3784227A1 (en) 2021-03-03
AU2025201393A1 (en) 2025-03-20
CN112384210A (zh) 2021-02-19
JP2021522344A (ja) 2021-08-30
CN120241690A (zh) 2025-07-04
EP3784227A4 (en) 2022-03-02
WO2019209943A1 (en) 2019-10-31
KR20210005662A (ko) 2021-01-14
JP2025011238A (ja) 2025-01-23
BR112020021812A2 (pt) 2021-02-23
CA3098360A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
CN120241690A (zh) 苏糖酸镁组合物及其用途
TWI241911B (en) Sustained release ranolazine formulations
CN104379138B (zh) 阿坎酸制剂、其使用方法及包含阿坎酸制剂的组合
US10555907B2 (en) Controlled-release solid dosage forms of mesalamine
EP2623099A1 (en) Composition and method for treating neurological disease
EP1942875B1 (en) Controlled release formulation
US20120039954A1 (en) Method of treating insomnia
JPH0696524B2 (ja) バルプロ酸をベ−スとした新規薬剤組成物及びその製法
CN104902880B (zh) 包含氢吗啡酮和纳洛酮的药物组合物
JPH07558B2 (ja) モピダモール製剤
TWI841539B (zh) 雙層醫藥錠劑調配物
EP1814529B1 (en) Dosage form time-lagged of drugs for the therapy of insomnia
US20180015080A1 (en) Compositions and methods for treatment in parkinson's disease patients
KR101277021B1 (ko) 위체류 약물 전달시스템을 이용한 경구용 방출제어형 레바미피드-함유 이층정 제제 및 그 제조방법
JP2665858B2 (ja) 持効性塩酸オキシブチニン製剤
TW200800155A (en) Gastric retentive gabapentin dosage forms and methods for using same
TW202313072A (zh) 檸檬酸鐵之兒科調配物
TWI764159B (zh) 口服組合物、製造方法及其用途
JPH07101867A (ja) 制酸剤組成物およびそれを用いた医薬組成物
CN121910679A (zh) 一种包含速释递送组合物和缓释递送组合物的组合及其制备方法和用途
JP2011068614A (ja) ビタミン製剤
HK1107282B (en) Dosage form time-lagged of drugs for the therapy of insomnia
WO2007010508A2 (en) Controlled release compositions of metaxalone
JP2009256237A (ja) 固形製剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination